Trastuzumab in the Treatment of Breast Cancer – New Developments

Christian Jackisch a Michael Untch b

a Klinik für Gynäkologie und Geburtshilfe und Brustzentrum Klinikum Offenbach GmbH,

b Frauenklinik/Interdisziplinäres Brustzentrum, Helios Klinikum Berlin-Buch, Akademisches LK der Universität Charité, Berlin, Germany

Key Words
Trastuzumab · Breast cancer · Adjuvant setting · Breast cancer, metastatic · HER-2/neu

Summary
Rarely a new drug has influenced the current concept of up-to-date systemic treatment in breast cancer like trastuzumab since the identification of the human epidermal growth factor receptor 2 and its implementation as strong prognostic as well as predictive factor. In human breast cancer, amplification of the HER-2/neu gene results in protein overexpression and poor prognosis. Patients whose tumors have HER-2/neu gene amplification have a shorter disease-free survival time than patients whose tumors exhibit a normal HER-2/neu gene copy number. HER-2/neu gene amplification identifies a biologically unique subset of aggressive breast tumors that are sensitive to growth inhibition and apoptosis induced by anti-HER-2/neu-targeted therapies. Trastuzumab therapy prolongs the survival of patients with metastatic HER-2/neu-overexpressing breast cancer when combined with chemotherapy and has recently been demonstrated to lead to dramatic improvements in disease-free survival when used in the adjuvant therapy setting in combination with or following chemotherapy. Most recent findings are suggesting that trastuzumab might be used in combination with chemotherapy as well as in combination with endocrine treatments, limited to patients presenting with metastatic disease. Still under debate are methods of proper HER-2/neu testing, patient selection, cardiotoxicity, duration of therapy, and directions for future research.

Schlüsselwörter
Trastuzumab · Mammakarzinom · Adjuvante Therapie · Mammakarzinom, metastasiertes · HER-2/neu

Zusammenfassung
Introduction

Approximately 20–25% of all primary breast cancers reveal an overexpression of the human epidermal growth factor HER-2/neu, a transmembraneous tyrosine kinase receptor, which is part of the HER family of receptors. HER-2/neu overexpression is associated with decreased disease-free and overall survival [1], indicating a key role of HER-2/neu in breast cancer pathogenesis and progression. The fact that trastuzumab given in metastatic breast cancer (MBC) leads to improved survival was regarded as a therapeutic revolution and the introduction of the era of targeted treatment in breast cancer. Based on these findings most of the clinical trials in all breast cancer settings, namely in the adjuvant and neoadjuvant setting, evaluated the incorporation of the human antibody in current or newly created therapeutic approaches. Thus, it was not a surprising observation that the speed of implementation of targeted treatments introducing trastuzumab was criticized as ‘insufficient to make reliable judgments’ by a leading international medical journal [2]. Until today trastuzumab has been implemented in all levels of breast cancer treatment, e.g. neoadjuvant, adjuvant as well as in the metastatic setting.

Recommended Assessment of HER-2/neu Overexpression

Early studies suggested that as many as 30% of breast cancers have HER-2 overexpression [3]. The frequency of HER-2/neu-positive breast cancer appears to be lower when considering all patients with a new diagnosis of invasive breast cancer. Yaziji et al. recently reported their experience with large volume testing and observed that 18% of samples tested (n = 2,913) showed gene amplification by fluorescent in situ hybridization: FISH, defined as a HER-2:CEP17 ratio > 2) [4]. Others observed a frequency of HER-2/neu overexpression of 20% among 116,736 specimens tested by immunohistochemistry (IHC) and 22.7% among 6,556 specimens tested by FISH [5]. The American Society of Clinical Oncology (ASCO) Tumor Marker Guidelines Panel has recommended routine testing of HER-2/neu on newly diagnosed and metastatic breast cancer since 2001 [6]. Following these recommendations HER-2/neu testing should be routinely performed in patients with a new diagnosis of invasive breast cancer (table 1).

Randomized Trials Adding Trastuzumab in the Adjuvant Setting

The findings of the 4 major randomized clinical trials involving more than 13,000 high-risk women with HER-2/neu-overexpressing breast cancer using trastuzumab for 52 weeks with or in sequence to chemotherapy were demonstrating a decrease of early risk of recurrence by 50%. More interestingly, adding 1 year of trastuzumab in node-positive breast cancer resulted in an absolute survival rate at 3 years of 94.3% in the trastuzumab group and 91.7% in the control group (absolute difference: 2.5 percentage points; 95% confidence interval, CI: 0.1–5.0 percentage points); at 4 years, the respective rates were 86.6% and 91.4% (absolute difference: 4.8 percentage points; 95% CI: 0.6–9.0 percentage points) [7]. The recent findings of the 2-year follow-up on the HERA trial demonstrated an unadjusted hazard ratio (HR) for the risk of death in the trastuzumab group compared with observation alone of 0.66 (95% CI: 0.47–0.91; p = 0.0115 by the log rank test), which corresponds with an absolute overall survival benefit of 2.7% (92.4% vs 89.7%) at 3 years. The HR for overall survival by censored analysis was 0.66 (95% CI: 0.45–0.87; p = 0.0051) (fig. 1) [8].

BCIRG 006: Results of the Second Planned Interim Analysis

The BCIRG 006 study was designed to maximize efficacy while minimizing toxicity in adjuvant trastuzumab-based therapies. Between April 2001 and March 2004, the study enrolled 3,222 women with early stage HER-2-positive breast cancer, with positive axillary lymph nodes (LN) as well as those without LN involvement (fig. 2). In the second interim

---

Table 1. Algorithm defining positive values for both HER-2 protein expression and gene amplification [6]

<table>
<thead>
<tr>
<th>Method</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHC</td>
<td>Uniform, intense membrane staining &gt;30% of tumor cells</td>
</tr>
<tr>
<td>FISH</td>
<td>&gt;6 HER-2 gene copies per nucleus</td>
</tr>
<tr>
<td>FISH ratio</td>
<td>HER-2 gene signals to chromosome 17 signals of more than 2.2</td>
</tr>
</tbody>
</table>

IHC = Immunohistochemistry; FISH = fluorescent in situ hybridization.
analysis, at a 3-year median follow-up, AC-TH and TCH significantly improved disease-free survival (DFS) and overall survival (OS) as compared to the control arm [9]. The relative reduction in the risk of relapse was 39% (p < 0.001) and 33% (p = 0.0003) respectively, for AC-TH and TCH vs control. The relative reduction in the risk of death was 41% (p < 0.0041) and 34% (p < 0.017) respectively, for AC-TH and TCH vs control.

In addition, the absolute DFS benefit at 4 years is similar for the two trastuzumab-containing arms (6% and 5% for AC-TH and TCH, respectively). Notably, the same level of DFS and OS benefit was also obtained for the 29% of node-negative patients enrolled in the study. In terms of safety, there was a significant difference in the major toxicity that has been consistently seen with trastuzumab-based therapies, i.e., cardiac toxicity.

Common to all adjuvant trials introducing trastuzumab was the evaluation of congestive heart failure and cardiac-related deaths. As mentioned above, the cardiac toxicity of the 2 experimental arms significantly favored the TCH regimen. No cardiac deaths were observed in either arm. There were 20 congestive heart failure events in the AC-TH arm versus 4 in the TCH arm. Moreover, there were 50% fewer asymptomatic declines in cardiac function in the TCH arm as compared to AC-TH.

Further, in terms of other toxicities, the TCH regimen appeared to also be more favorable than the AC-TH regimen.

**Impact of Topoisomerase-II-alpha (topo-II-α)**

An unplanned retrospective subgroup analysis of coamplification of topo-II-α and HER-2/neu was done in 2,120 patients from the BCIRG-006 trial and suggested that the incremental benefit of AC-TH over TCH was confined to patients with coamplification of HER-2/neu and topo-II-α, which is located in the same amplicon as HER-2/neu on chromosome 17q and is one of the targets of anthracycline chemotherapy [10]. Coamplification of the topo-II-α gene occurred in approximately 35% of HER-2/neu-positive patients and seemed to confer a therapeutic advantage to anthracycline/trastuzumab-based combination regimens. Patients with HER-2/neu-positive tumors that did not have coamplification of topo-II-α, either deletion (4%) or no amplification (60%), did not receive the same benefit, and such patients might be candidates for efficacious, nonanthracycline-based regimens, avoiding potential cardiac toxicity. The most recent update of the BCIRG 006 trial failed to show the previous finding of such benefit, furthermore this target was not predictive for selecting one of the given chemotherapy regimens [9]. Thus, up to date there is no need for the routine assessment of topo-II-α as predictive marker in the adjuvant setting. This remains an interesting exploratory finding, but further confirmatory data are needed before any treatment guidelines can be recommended based on topo-II-α amplification.

**Optimal Duration of Trastuzumab in the Adjuvant Setting**

Despite the availability of the results of all major adjuvant trials the optimal duration of trastuzumab exposure remains unclear. The suspected duration of one year exposure to trastuzumab, as used in the majority of trials, was seriously challenged by the release of the FinHer trial [11]. This trial showed a significant advantage to the use of trastuzumab for only 9 weeks in the adjuvant therapy setting (in combination with docetaxel or vinorelbine). The study involved 1,010 patients randomized to docetaxel every 3 weeks for 3 doses versus 9 weeks of vinorelbine followed, in both groups, by three 3-week cycles of cyclophosphamide, epirubicin, and 5-fluourouracil (CEF). The 232 patients found to have HER-2/neu-positive breast cancer by FISH were randomized to receive weekly trastuzumab for 9 weeks alone with docetaxel and vinorelbine. At a median follow-up of 3 years, adjuvant trastuzumab was effective in preventing breast cancer recurrences (HR: 0.46; p = 0.0078). In the group of patients assigned to trastuzumab treatment, the left ventricular ejection fraction (LVEF) was measured by either echocardiography or radionuclide ventriculography using multi-gated acquisition (MUGA) scan before chemotherapy, after the last CEF cycle, and 12 and 36 months after chemotherapy. One patient had cardiac infarction and 3 had cardiac failure; none of these 4 patients had received trastuzumab. LVEF was preserved in women who received trastuzumab. Four women treated with trastuzumab (3.5%) and 7 who were not (6.0%) had one or more LVEF measurements >15% lower than the pretreatment value. A >10% decrease, resulting in an LVEF of <50%, occurred in 3 patients, none of whom had received trastuzumab.

These findings challenged for the first time the optimal duration of trastuzumab exposure, while the HERA trial is still
in summary the following statements can be made:
1. Adjuvant trastuzumab treatment for 1 year in HER-2/neu overexpressing breast cancer patients in addition to chemotherapy can significantly improve disease free and overall survival.
2. This benefit is seen in node positive and node negative disease.
3. Open questions are longer versus shorter duration of treatment, anthracycline free adjuvant chemotherapy, duration of treatment and long term outcome.

References


Under investigation for the efficacy data of the two-year treatment with trastuzumab.

Optimal duration of exposure to trastuzumab remains unknown so far. Moreover it has been shown that the risk for cardiotoxicity is increased in patients treated with trastuzumab, particularly in those who have received an adjuvant chemotherapy containing an anthracycline [7–9,11,12]. In this context, French Institut National du Cancer (INCa) proposes a randomized clinical trial aimed at evaluating the non-inferiority, in terms of disease-free survival and cardiotoxicity, of a reduction of exposure to trastuzumab comparing 6 months versus 12 months after stratification by the mode of administration of chemotherapy (concomitant or sequential). This trial aims at being pragmatic, including a very large number of patients, with a follow-up as close as possible to that of routine clinical practice. The objective is to include all patients receiving an adjuvant treatment with trastuzumab in order to recruit 7,000 patients as soon as possible, within an 18-month inclusion period (fig. 3) [13].